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Abstract
Background—Infections are an important cause of morbidity and mortality after burn injuries. 
Here, we describe the timeline of infections and pathogens after burns.
Methods—A retrospective study was performed in a large tertiary care burn center from 2004 
through 2013. Analyses were performed on healthcare-associated infections (HAI) meeting 
Centers for Disease Control and Prevention criteria and on all positive cultures. Incidence rates 
(IR) per 1,000 days were calculated for specific HAI categories and pathogens, and across 
hospitalization time (week 1, 2–3 and 4+).
Results—Among 5,524 patients the median burn size was 4% of total body surface area 
(interquartile range, 2–10%). 7% of patients developed an HAI, of whom 33% had more than one 
HAI episode. Gram-positive bacteria were isolated earlier and Gram-negative later during 
hospitalization. Of 1,788 bacterial isolates, 44% met criteria for multi-drug resistance and 23% for 
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extensive drug resistance. Bacteria tended to become increasingly resistant to antibiotics as time 
from admission increased.
Conclusions—We observed differences in infection type, pathogen and antibiotic resistant 
bacterium risk across time of hospitalization. These results may guide infection prevention in 
various stages of the post-burn admission.
Keywords
burn; intensive care unit; healthcare-associated infection; timing; bloodstream infection; 
pneumonia
Introduction
Burn injuries remain an important source of morbidity and mortality in the United States. An 
estimated 450,000 burn injuries require medical treatment, and 3,400 deaths are related to 
fires and burns per year in the US1. Burn patients are vulnerable to infections, and especially 
to infections with multidrug-resistant organisms2, 3. In the US, infections caused by resistant 
organisms add between $21 billion and $34 billion to health care costs annually, as 
compared to susceptible organisms4.
Outcomes after burn injuries vary; data from the National Burn Repository (NBR) shows 
high variability in mortality rates (2% to 12% hospital mortality) in high-volume centers, 
even after adjustment for burn severity5. This variability remains mostly unexplained, but is 
likely related to factors such as distribution of comorbidities including substance abuse, and 
infection rates. A burn injury results in an immunocompromised state; both through 
breakdown of the skin natural barrier function as well as through systemic mechanisms6–9. 
Unlike other immunocompromised host populations, few studies have been performed that 
describe the timeline of infections and infectious pathogens after burn injuries10. Here, we 
describe the timing of specific infections and pathogens during hospitalization in a large 
cohort of patients with burns.
Materials and Methods
Study Population and Design
All patients admitted to the burn unit of a large tertiary care referral burn center between 
01/01/2004 and 12/31/2013 were included. Patients were identified through the North 
Carolina Jaycee Burn Center Registry, which includes data collected as part of participation 
in the National Burn Repository. Data were obtained from the NC Jaycee Burn Center 
Database, electronic health record, laboratory databases, and chart review. In addition, all 
data on healthcare-associated infections (HAI) was obtained from the Hospital 
Epidemiology database, which includes hospital-wide surveillance for all HAI defined by 
the Centers for Disease Control and Prevention (CDC) and performed in accordance with 
CDC criteria11.
The first hospital admission for each patient aged 18 years or older was reviewed. The data 
available from all data sources were merged and as needed additional medical record 
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reviews were performed. Patients with missing discharge dates were excluded (n=36). This 
study was approved by the Institutional Review Board of the University of North Carolina.
Microbiology
All microbial isolates from all clinical cultures were considered “potential pathogens”. In 
addition, for viral pathogens, the results of nucleic acid amplification tests performed on 
blood, cerebrospinal fluid, or skin lesions were used as evidence of viral replication. No 
attempt was made in this study to distinguish colonization from infection. For bacterial 
isolates, the definitions outlined by Magiorakos et al. were used to define multidrug-resistant 
(MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacteria12. For 
Achromobacter sp. and Burkholderia spp. MDR, XDR, and PDR resistance was determined 
using Pseudomonas drug-resistance definitions. MDR status for Stenotrophomonas 
maltophilia and Streptococcus pneumoniae was determined by non-susceptibility to 
trimethoprim/sulfamethoxazole or penicillin, respectively. Enterobacteriaceae were further 
divided based on resistance to fluoroquinolones (FRE), presence of an extended spectrum 
beta-lactamase (ESBL) phenotype as per CDC guidelines (ESBL-E), and resistance to 
carbapenems (CRE).
Covariates
The revised Baux score was calculated for each patient, as described13. The Charlson 
Comorbidity Index was also calculated for each patient, as described14 Total burn surface 
area (TBSA) was potentially reported multiple times across data sources; if multiple TBSA 
values were identified, an average TBSA was computed and used for analysis. Burn 
mechanisms were reported as per NBR guidelines (contact, chemical, electrical, flame, 
radiation, scald, and other)5.
Statistical Analysis
Patients were followed from date of admission until death or hospital discharge. Incidence 
rates (IR) and 95% confidence intervals (CI) were calculated based on a Poisson 
distribution, and expressed as number of cases per 1,000 days. IRs and corresponding 
measures of precision were calculated for specific HAI categories and microbes. Time 
hospitalized was categorized by week of hospitalization, including Week 1 (0–7 days after 
admission for pathogens, 2–7 days after admission for HAIs), Weeks 2–3 (8–21 days after 
admission), and Weeks 4+ (22 or more days after admission). Differences in infection rates 
across hospitalization time intervals were compared using likelihood ratio tests from Poisson 
regression models. The 90-day cumulative incidence of specific HAIs and pathogens were 
calculated using Kaplan-Meier survival curves. Only patients at risk for HAIs as per CDC 
guidelines (i.e. hospitalized for ≥2 days) were included in HAI analyses.
All analyses were performed using SAS software version 9.3 (SAS Inc., Cary, NC).
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Results
Patient and Burn Characteristics
From 2004 to 2013, 5,524 adult patients with burn injuries were included in this study. The 
median age was 42.3 years (interquartile range [IQR] 29.7–54.8 years), 73% of patients 
were male, and 53% were white (Table 1). The most common mechanisms of burn were fire/
flame (53%), and scald (31%) injury. In addition, 461 (8.4%) patients had inhalational injury 
upon admission. The median burn size as defined by percentage of total body surface area 
(%TBSA) was 4%TBSA (IQR 2% – 10%TBSA). The median revised Baux score was 49.9 
(IQR 36.0–64.9). When individually calculated per patient, this corresponded to a median 
estimated predicted mortality of 0.54% (IQR 0.19%–1.54%)13.
Hospitalizations
The median length of stay was 8 days (IQR 2–10 days), however, 595 (10.8%) of patients 
had a prolonged hospitalization of >30 days, and 124 (2.4%) of patients were in the hospital 
for >90 days. 1,832 (33.2%) patients were admitted to the intensive care unit. The overall 
hospital mortality rate was 4.4%.
Healthcare-associated infections
When analyzing the first specific HAI of its type per patient, a total of 631 HAI events were 
diagnosed among 383 (7%) patients over total follow-up time of 81,171 days (Table 2). 
Among patients with at least one HAI, 257 (67%) had 1, 73 (19%) 2, 29 (8%) 3, and 24 
(6%) ≥4 HAI events during their hospitalization. The most common HAIs were bloodstream 
infections (25%), skin and soft tissue infections (19%), catheter-associated urinary tract 
infections (14%), and ventilator-associated pneumonia (VAP, 13%). The cumulative 
probability of being diagnosed with a HAI increased with additional time hospitalized, such 
that almost 50% of patients remaining hospitalized 80 days from admission had experienced 
at least one HAI. In general, skin and soft tissue infections were the first to occur after 
admission, with a median time from admission of 3 days (IQR 3–11), followed by 
respiratory infections, with a median time from admission of 30 days (IQR 14–66.5), and C. 
difficile infections, with a median time from admission of 35.5 days (IQR 9–77). Overall, 
bloodstream and urinary tract infections occurred later in the admission at a median of 41 
days (IQR 15–76 days), and 41 days (IQR 12–73 days) after admission, respectively. The 
incidence rate of BSI increased from 1.27 (95% CI 0.84–1.93) in the first week after 
admission to 1.32 (95% CI 0.92–1.90) in weeks 2–3, and to 2.66 (95% CI 2.08–3.39) in 
week 4 and later, incident cases per 1,000 patient/days (Table 2). The 90-day cumulative 
incidence of skin and soft tissue infections, urinary tract infections, respiratory infections 
and bloodstream infections are shown in Figures 1A and 1B.
Potential Pathogens
The five most common pathogen classes were Enterobacteriaceae (37%), Staphylococcus 
aureus (26%), coagulase-negative Staphyloccocci (22%), Candida spp. (19%), and 
Pseudomonas spp. (17%). Overall, 774 (14%) patients had at least one potential pathogen 
reported from clinical cultures or viral PCR. 878 potential pathogens were recovered from 
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these 774 patients; 298 (5%) had 1 potential pathogen isolated, 164 (3%) had 2 potential 
pathogens isolated, 97 (2%) had 3 potential pathogens isolated, and 215 (4%) had 4 or more 
potential pathogens isolated. Of note, two outbreaks with Acinetobacter baumannii occurred 
in the time periods 9/2007 to 4/2008 and 1/2009 to 9/201015.
In patients who had at least one positive culture, the time to first positive culture with any 
potential pathogen was 4 days (IQR 2–11 days). Streptococci spp., S. aureus, Enterococcus 
spp. and other Gram-positive pathogens were generally the first to be found after admission, 
with median times to isolation of 2 days (IQR 1–3 days), 3 days (IQR 2–8 days), 9 days 
(IQR 3–33 days), and 6.5 days (IQR 2–29 days), respectively. In contrast, 
Enterobacteriaceae, Pseudomonas sp., and Acinetobacter sp. tended to occur later during 
hospitalization at a median of 11.5 days (IQR 4–26 days), 18days (IQR 9–36 days), and 26 
days (IQR 14–59 days), respectively.
Antibiotic Resistance
Antibiotic resistance was assessed for the following bacteria: Enterococcus sp., S. aureus, S. 
pneumoniae, Achromobacter sp., Acinetobacter sp., Burkholderia sp., Enterobacteriaceae, 
Pseudomonas sp., and S. maltophilia. Among these pathogens, 1,788 bacterial isolates 
derived from 543 unique patients were tested for antibiotic susceptibility; 793 (44%) met the 
criteria for MDR, and 416 (23%) met the criteria for XDR. No isolates met the criteria for 
PDR. MDR isolates tended to be isolated later in the hospitalization as compared to non-
MDR bacterial isolates (Table 3); the median time from admission to first MDR isolation 
was 38 days (IQR 17–77 days), as compared to 11 days (IQR 3–44 days) for non-MDR 
isolates. This trend towards isolation later in the hospital course was seen in all major 
pathogen classes (Table 3). Among Gram-positive pathogens, the median time from 
admission to first positive culture for methicillin-resistant S. aureus (MRSA) was 11.5 days 
(IQR 3–33 days), as compared to 3 days (IQR 2–5 days) for methicillin-susceptible S. 
aureus (MSSA).
As Gram-positive organisms were overall less common later during admission, the incidence 
rates of both MRSA and MSSA decreased over time since admission. However, in week 1 
MSSA was more common with an incidence rate of 3.04 (95% CI 2.44–3.77), as compared 
to MRSA with 1.38 (95% CI 1.00–1.90) incident cases per 1,000 patient/days, respectively. 
In contrast, in the time period of 4 weeks and later after admission, MSSA became 
significantly less common as MRSA with MSSA rates decreasing to 0.11 (95% CI 0.04–
0.34), while MRSA rates had a less marked decrease to 0.69 (95% CI 0.45–1.08) incident 
cases per 1,000 patient/days, respectively (Table 3). The cumulative incidence of MRSA and 
MSSA are shown in Figure 1c.
In Enterococci, the median time from admission to first positive culture was 27.5 days (IQR 
13–90 days) for vancomycin-resistant Enterococci (VRE) as compared to 7 days (IQR 3–33 
days) for vancomycin-susceptible Enterococci (VSE). The cumulative incidence of VRE and 
VSE are shown in Figure 1d.
Similarly, for Enterobacteriaceae, the median time to first positive culture was 12 days (IQR 
4–29 days) for fluoroquinolone-susceptible isolates, 44 days (IQR 21–82 days) for FRE, 52 
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days (IQR 8–90 days) for ESBL-E, and 59 days (IQR 34–98 days) for CRE. Rates of 
fluoroquinolone-susceptible Enterobacteriaceae were not different during the three analyzed 
time periods. In contrast, for all 3 resistance phenotypes of Enterobacteriaceae, incidence 
rates increased with increasing time after admission (Table 3). The cumulative incidence of 
FRE, ESBL-E, CRE, and susceptible Enterobacteriaceae are shown in Figure 1e.
For patients with Pseudomonas spp., the median time from admission to first MDR 
Pseudomonas sp. isolation was 52.5 days (IQR 28–106 days), as compared to 22 days (IQR 
11–51 days) for non- MDR Pseudomonas spp. The incidence rate of non-MDR 
Pseudomonas spp. decreased significantly (1.46 [95% CI 1.21–1.76] in week 1 to 0.87 [95% 
CI 0.58–1.31] in weeks 4 and after, incident cases per 1,000 patient/days, respectively), 
while the incidence rate of MDR Pseudomonas spp. increased (0.04 [95% CI 0.00–0.26] in 
week 1 to 1.85 [95% CI 1.40–2.44] in weeks 4 and after, incident cases per 1,000 patient/
days, respectively). The cumulative incidence of MDR Pseudomonas sp. and non-MDR 
Pseudomonas sp. are shown in Figure 1e.
Discussion
In this study, we have provided a comprehensive evaluation of common healthcare-
associated infections and potential pathogens in order to provide a framework for a timeline 
of infections after hospitalization for burn injuries. We found that skin and soft tissue 
infections occurred early during admission, whereas respiratory tract infections and 
bloodstream infections represent later complications after burns. These data specifically 
represent healthcare-associated infections that met criteria from the CDC. Therefore, no 
patients who presented with a delayed presentation of an infected burn would be included in 
the skin and soft tissue infection group. Regarding specific pathogens, we found a 
predominance of Gram-positive pathogens early on during hospitalization, shifting to Gram-
negative bacteria later during hospitalization. As expected, antibiotic-resistant pathogens 
tended to be isolated later during hospitalization as well. The findings of a number of 
smaller studies (n ranging from 51 to 94 patients) showed similar trends16–18. For instance, 
in a study on VAP in a Belgian burn unit, MDR organisms increased from 9% in early-onset 
infection to 32% in late infection17. In addition, in a 6-year study from a military burn unit, 
the percentages of 4 major pathogens – A. baumannii, P. aeruginosa, K. pneumoniae, and S. 
aureus – that were susceptible to main antibiotic classes were compared between the first 5 
days and days 15–30 of hospitalization. Similar to our findings, they observed that for all 
pathogen-antibiotic combinations, the susceptibility rates were lower as patients were 
admitted longer10.
In several ways, patients with burns are similar to other immunocompromised patients such 
as recipients of solid organ or hematopoietic stem cell transplants. In those populations, 
timelines of expected infections during specific periods of exposures and 
immunosuppression have been well-described and put into clinical use19, 20. In addition to 
interfering with the local immune barrier of the skin, burns have a variety of central 
immunomodulatory effects. Amongst others, reported effects include a skew towards 
production of Th17 T cells, alterations in the expression of immune signaling genes, 
increased Toll-like receptor-4 expression, and dendritic cell dysfunction6–9. Therefore, we 
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propose that in the burn population – similar to other immunocompromised populations – 
knowledge of when certain infections are likely to occur will be beneficial in guiding 
empiric treatment as well as preventative strategies. In addition, infection preventionists who 
care for burn populations may use these data to evaluate not just the overall incidence of 
specific infections and MDR organisms, but also their incidence as it relates to the timing of 
the admission.
Infections are an important threat to the healing process of burn patients. In addition to 
immune alterations, patients have several risk factors for healthcare-associated infections. 
These risk factors include prolonged exposure to the hospital environment, large open 
wounds both from the primary burn site as well as from graft sites, inhalational injury, and 
frequent use of invasive devices such as intravenous and arterial catheters, endotracheal 
tubes, tracheostomies, and indwelling urinary catheters. We have previously reported on 
trends over time of healthcare-associated infections in our burn unit21–23. Specifically, we 
noted that the rates of catheter-associated bloodstream infections (CLABSI) decreased 
during the last decade, whereas respiratory tract infections remained more stable. The 
decrease in CLABSI rates likely resulted from a bundled approach of several 
interventions21. A controversial component of this bundle is the practice of frequent line 
changes which has not been shown to be beneficial in other intensive care settings. Current 
guidelines from the Healthcare Infection Control Practices Advisory Committee (HICPAC) 
recommend against scheduled line changes as a means of decreased CLABSI rates24. 
However, it should be noted that these recommendations are based on two small older trials 
that did not include burn patients25, 26. Therefore, these recommendations may or may not 
apply to current patients with burn injuries. A recommended component is the use of 
chlorhexidine for bathing, which is employed at our burn unit. In a small study that used 
historical controls, the introduction of daily chlorhexidine bathing decreased rates of VAP 
and CLABSI to zero27.
Antibiotic usage is very common in the burn population28. This antibiotic exposure 
combined with other risk factors increase the risk for acquisition of multidrug-resistant 
bacteria. In our cohort, almost half of pathogens met criteria for multi-drug resistance, with 
more than half of those MDR organisms being in the extensively drug resistant category. The 
rise of MDR organisms is an extremely worrisome finding that has been reported in other 
burn centers worldwide29–31. Infections with MDR organisms are associated with increased 
time to effective therapy, increased mortality, increased length of stay and increased health 
care costs, as compared to infections with susceptible bacteria32, 33. These risks are 
especially important in burn patients, given their prolonged hospitalizations and risk for 
recurrent infections.
Our study has several limitations. It is a retrospective study, and specimens were collected 
based on clinical need rather than as part of a prospective research strategy. Nonetheless, our 
findings are representative of a “real-world” experience in a large burn center. In addition, 
the determination of healthcare-associated infections was made in real-time by infection 
preventionists following standardized definitions. Another limitation is that this study was 
conducted in a single burn center. It is possible that these findings may not completely 
translate to other centers. However, the observed patterns of shifts during hospitalization 
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from Gram-positives to Gram-negatives and to increasing antimicrobial resistance are 
intuitive, biologically plausible, and were also found in smaller studies performed at other 
centers16–18. Finally, we have evaluated all pathogens that were recovered from clinical 
cultures, without attempting to determine infection vs. colonization, which was outside of 
the scope of the current study.
Conclusions
We have analyzed in detail the timeline of infections during hospitalization for a burn injury. 
Skin and soft tissue infections tend to occur early in hospitalization, followed by respiratory 
tract infections and even later bloodstream infections. Gram-positives are more common in 
the first days of hospitalization, whereas Gram-negative bacteria predominate during later 
phases. Importantly, multidrug resistant pathogens tend to occur later as well. These findings 
may have important implications for the empiric treatment and diagnostics of patients with 
burns who are suspected of having an infection.
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Highlights
• Seven percent of patients with burn injuries develop a hospital-acquired 
infection
• Gram-positive bacteria predominate early during the hospitalization after burn 
injury, whereas Gram-negative bacteria become more common later during 
the admission.
• Bacterial pathogens isolated from burn patients tend to become resistant to an 
increasing number of antibiotics as time from admission increases.
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Figure 1. 
90-day cumulative incidences of A) skin and soft tissue infections and urinary tract 
infections, B) respiratory infections and bloodstream infections, C) methicillin-susceptible 
S. aureus (MSSA) and methicillin-resistant S. aureus, D) vancomycin-susceptible 
Enterococcus sp. (VSE) and vancomycin-resistant Enterococcus sp. (VRE), E) non-multi-
drug resistant (MDR) Enterobacteriaceae, fluoroquinolone-resistant Enterobacteriaceae 
(FRE), extended-spectrum-β-lactamase-producing Enterobacteriaceae (ESBL-E) and 
carbapenem-resistant Enterobacteriaceae (CRE) and F) non-MDR and MDR Pseudomonas 
sp.
Calculated using Kaplan-Meier estimates.
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Table 1
Demographics and clinical characteristics of patients with burn injuries.
Characteristic
All 5,524
Male 4,011 (72.6)
Race/Ethnicity
White 2,952 (53.4)
Black 1,462 (26.5)
Hispanic 309 (5.6)
Other 801 (14.5)
Age, median (IQR) 42.3 (29.7–54.8)
Charlson Comorbidity Index, median (IQR) 1 (0–2)
Burn size (%TBSA*), median (IQR) 4.0 (2.0–10.0)
Burn mechanism
Flame 2,936 (53.2)
Scald 1,703 (30.8)
Contact 286 (5.2)
Chemical 235 (4.3)
Electrical 218 (4.0)
Radiation 14 (0.3)
Other Burn 107 (1.9)
Unknown 25 (0.5)
Inhalation injury 461 (8.4)
Revised Baux score, median (IQR)† 49.9 (36.0–64.9)
Length of stay-in days, median (IQR) 8 (2–14)
ICU admission 1,832 (33.2)
Mechanical ventilation 740 (13.4)
Disposition
Death 243 (4.4)
Home 4,903 (88.8)
Long term care facility 248 (4.5)
Other‡ 130 (2.4)
All data are shown as n (%), unless otherwise noted.
*
TBSA total body surface area.
†
Revised Baux score defined as age (years) + %TBSA (+17 if inhalational injury is present).
‡Other disposition includes transfers to another hospital units, acute care facilities, mental health facilities or substance abuse programs, and 
unknown alive disposition. IQR: interquartile range
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